2023 World Conference on Lung Cancer (Posters)-P2.09. Aumolertinib Combined with Carbamazepine and Intrathecal Pemetrexed for EGFR-mutated LM NSCLC with Symptomatic Epilepsy

P2.09. Aumolertinib Combined with Carbamazepine and Intrathecal Pemetrexed for EGFR-mutated LM NSCLC with Symptomatic Epilepsy - PDF(Abstract)

Back to course

Pdf Summary

This document outlines the details of a clinical trial for the treatment of EGFR-mutated leptomeningeal metastasis (LM) in non-small cell lung cancer (NSCLC) using a combination of drugs. Leptomeningeal metastasis is a serious complication of NSCLC, and traditional treatments have limited effectiveness and high toxicity. <br /><br />The trial, which is a phase II clinical trial, aims to evaluate the clinical efficacy of a combination therapy consisting of aumolertinib (a third-generation EGFR-TKI), intrathecal pemetrexed (a chemotherapeutic drug), and carbamazepine (an antiepileptic drug) in patients with symptomatic epilepsy associated with LM. <br /><br />The study is being conducted by a team of researchers from several hospitals in China. The team has previously conducted a phase II trial of intrathecal pemetrexed, which showed promising results in improving overall survival in LM patients. <br /><br />The primary endpoint of the trial is median overall survival and the control rate of anti-epileptic treatment. Secondary endpoints include safety, progression-free survival, and objective response rate. <br /><br />The methods of the trial involve administering the drugs through intrathecal injection and oral administration, and regular follow-up examinations to monitor the patients' condition. Additionally, whole-exome sequencing comparison technology will be used to study changes in cerebrospinal fluid gene detection and explore the molecular mechanisms of LM at the gene level. <br /><br />The trial plans to enroll 20-25 EGFR mutant NSCLC patients with symptomatic epilepsy and LM. Keyword references in this document include aumolertinib, intrathecal injection, and symptomatic epilepsy. <br /><br />The trial aims to provide a new treatment option for patients with EGFR-mutated LM, particularly those with symptomatic epilepsy, and to expand our understanding of the molecular mechanisms involved in LM. This study is considered an original work that can provide new insights into the combination of drugs for LM patients with symptomatic epilepsy.

Asset Subtitle

Li Li

Meta Tag

Speaker Li Li

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

clinical trial

EGFR-mutated leptomeningeal metastasis

non-small cell lung cancer

combination therapy

aumolertinib

intrathecal pemetrexed

carbamazepine

symptomatic epilepsy

overall survival

anti-epileptic treatment